Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 8Terminated 3Withdrawn 2Unknown 1

Sponsor Class

OTHER 35NIH 9OTHER_GOV 4UNKNOWN 2NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Cisplatin 15Paclitaxel 14Taxes 10Cyclophosphamide 9Carboplatin 9Gemcitabine 7Platinum 61,2-diaminocyclohexaneplatinum II citrate 6Trastuzumab 5Radiotherapy 5Oxaliplatin 5Doxorubicin 5Docetaxel 5Cytarabine 5Capecitabine 5Brachytherapy 5fludarabine 4Rituximab 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Fluorouracil 4Dexamethasone 4Watchful Waiting 3Radiotherapy, Conformal 3Pemetrexed 3Nimorazole 3Lenalidomide 3Imatinib Mesylate 3Idarubicin 3Gene Expression Profiling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × NETWORK × Thalidomide × Clear all
NCT01532856 2012-02-15

Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years

Grupo de Estudos Multicentricos em Onco-Hematologia

Phase 3 Unknown
64 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡